Embecta Corp (EMBC)
13.82
-0.18
(-1.29%)
USD |
NASDAQ |
Nov 22, 16:00
13.86
+0.04
(+0.33%)
After-Hours: 20:00
Embecta Revenue (Quarterly): 272.50M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 272.50M |
March 31, 2024 | 287.20M |
December 31, 2023 | 277.30M |
September 30, 2023 | 281.90M |
June 30, 2023 | 286.10M |
March 31, 2023 | 277.10M |
December 31, 2022 | 275.70M |
September 30, 2022 | 274.60M |
Date | Value |
---|---|
June 30, 2022 | 291.10M |
March 31, 2022 | 274.50M |
December 31, 2021 | 289.30M |
September 30, 2021 | 300.80M |
June 30, 2021 | 295.00M |
March 31, 2021 | 284.20M |
December 31, 2020 | 285.30M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
272.50M
Minimum
Jun 2024
300.80M
Maximum
Sep 2021
283.51M
Average
284.20M
Median
Mar 2021
Revenue (Quarterly) Benchmarks
Boston Scientific Corp | 4.209B |
Abbott Laboratories | 10.64B |
Nevro Corp | 96.91M |
iRhythm Technologies Inc | 147.54M |
Inari Medical Inc | 153.39M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 14.70M |
Total Expenses (Quarterly) | 216.60M |
EPS Diluted (Quarterly) | 0.25 |
Enterprise Value | 2.123B |
Gross Profit Margin (Quarterly) | 69.76% |
Profit Margin (Quarterly) | 5.39% |
Earnings Yield | 8.68% |
Operating Earnings Yield | 21.15% |
Normalized Earnings Yield | 8.683 |